-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Celecoxib + Famciclovir) in Fibromyalgia (Fibromyalgia Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Celecoxib + Famciclovir) in Fibromyalgia (Fibromyalgia Syndrome) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Celecoxib + Famciclovir) in Fibromyalgia (Fibromyalgia Syndrome) Drug Details:...
-
Product Insights
Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) - Drugs In Development, 2023’, provides an overview of the Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Encephalomyelitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Encephalomyelitis - Drugs In Development, 2023’, provides an overview of the Encephalomyelitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Encephalomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Fibromyalgia (Fibromyalgia Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Fibromyalgia (Fibromyalgia Syndrome) - Drugs In Development, 2023’, provides an overview of the Fibromyalgia (Fibromyalgia Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fibromyalgia (Fibromyalgia Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vemircopan in IgA Nephropathy (Berger’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vemircopan in IgA Nephropathy (Berger's Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vemircopan in IgA Nephropathy (Berger's Disease) Drug Details: Vemircopan...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CC-97540 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CC-97540 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-97540 in Follicular Lymphoma Drug Details: CC-97540 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Celecoxib + Famciclovir) in Chronic Fatigue Syndrome (Myalgic Encephalomyelitis)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.(Celecoxib + Famciclovir) in Chronic Fatigue Syndrome (Myalgic Encephalomyelitis)Drug Details:IMC-1 a fixed dose combination of celecoxib...
-
Company Profile
Virios Therapeutics, Inc – Company Profile
Virios Therapeutics, Inc (Virios Therapeutics), formerly Innovative Med Concepts LLC is a biotech company that develops novel treatments for the treatment of fibromyalgia and other related syndromes. The company’s pipeline products include NRP-1, a throat spray that is used to treat viral pharyngitis that provides relief to cancer patients undergoing head and neck radiation; and IMC-1, a novel proprietary fixed dose combination medication that is designed to treat chronic tissue-resident herpes simplex virus type 1. It also conducts research on...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (celecoxib + famciclovir)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (celecoxib + famciclovir) Drug Details IMC-1 a fixed dose combination of celecoxib and famciclovir...
-
Product Insights
Irritable Bowel Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of irritable bowel syndrome include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite, and constipation. These symptoms can be triggered by food, stress, and hormones. The Irritable Bowel Syndrome pipeline market research report provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the...